Reduced Endothelial Progenitor Cell Number and Function in Inflammatory Bowel Disease: A Possible Link to the Pathogenesis

Garolla, Andrea; D’Incà, R.; Checchin, D.; Biagioli, Andrea; Toni, Luca De; Nicoletti, Valentina; Scarpa, Marco; Bolzonello, Elisa; Sturniolo, Giacomo Carlo

doi:10.1038/ajg.2009.332

Cited by 32 publications

(39 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To eliminate this difficult transition, we have always used human cells throughout our initial research. However, multiple studies have clearly demonstrated that donor age and health status can dramatically affect cell behavior [Phillips et al, 1994;Becerra et al, 1996;Michel et al, 1996;Mogford et al, 2002;Heeschen et al, 2004;Zhang et al, 2005;Garolla et al, 2009;Krenning et al, 2009;Westerweel and Verhaar, 2009]. Thus, the second translational step was to use age-and risk-matched human cells.…”

Section: Preclinical Studies With the Lifeline Tm Graftmentioning

confidence: 99%

The Evolution of Vascular Tissue Engineering and Current State of the Art

Peck

Gebhart²,

Dusserre³

et al. 2011

Cells Tissues Organs

158

122

View full text Add to dashboard Cite

Dacron® (polyethylene terephthalate) and Goretex® (expanded polytetrafluoroethylene) vascular grafts have been very successful in replacing obstructed blood vessels of large and medium diameters. However, as diameters decrease below 6 mm, these grafts are clearly outperformed by transposed autologous veins and, particularly, arteries. With approximately 8 million individuals with peripheral arterial disease, over 500,000 patients diagnosed with end-stage renal disease, and over 250,000 patients per year undergoing coronary bypass in the USA alone, there is a critical clinical need for a functional small-diameter conduit [Lloyd-Jones et al., Circulation 2010;121:e46–e215]. Over the last decade, we have witnessed a dramatic paradigm shift in cardiovascular tissue engineering that has driven the field away from biomaterial-focused approaches and towards more biology-driven strategies. In this article, we review the preclinical and clinical efforts in the quest for a tissue-engineered blood vessel that is free of permanent synthetic scaffolds but has the mechanical strength to become a successful arterial graft. Special emphasis is given to the tissue engineering by self-assembly (TESA) approach, which has been the only one to reach clinical trials for applications under arterial pressure.

show abstract

Section: Preclinical Studies With the Lifeline Tm Graftmentioning

confidence: 99%

The Evolution of Vascular Tissue Engineering and Current State of the Art

Peck

Gebhart²,

Dusserre³

et al. 2011

Cells Tissues Organs

158

122

View full text Add to dashboard Cite

show abstract

“…Garolla et al [1] reported a lower number of circulating EPCs in CD patients compared to controls, demonstrating that apoptosis is the principal pathway for EPC reduction. Contrary to the previous study, Masuda et al [9] reported no significant reduction in the number of circulating EPCs among CD patients as compared to controls.…”

mentioning

confidence: 99%

“…T cells, expansion of the intestinal microvasculature, and endothelial impairment [1,2]. Approximately 565,000 residents of the USA are diagnosed with CD each year.…”

mentioning

confidence: 99%

“…In this context, hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), endothelial progenitor cells (EPCs), resident stem cells of intestine, and induced pluripotent stem cells (iPSCs) could be helpful in IBD therapy. Studies in the last several years suggest that endothelial impairment substantially contributes to the onset and progression of and recovery from inflammatory conditions [1]. EPCs, derived from bone marrow hematopoietic stem cells, (HSCs) have the capability to migrate to the site of endothelial damage through the peripheral circulation and have been used to treat several inflammatory diseases, ischemic limb disease, peripheral vascular disease, and coronary heart disease [6][7][8].…”

mentioning

confidence: 99%

“…Despite these successes, the effectiveness of circulating EPCs in the amelioration of CD remains speculative [1,9,10]. Garolla et al [1] reported a lower number of circulating EPCs in CD patients compared to controls, demonstrating that apoptosis is the principal pathway for EPC reduction.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Circulating Endothelial Progenitor Cells in Crohn’s Disease: An EPiC in the Making?

Dietrich

Singh

2017

Dig Dis Sci

View full text Add to dashboard Cite

Distinct contribution of human cord blood-derived endothelial colony forming cells to liver and gut in a fetal sheep model

et al. 2012

View full text Add to dashboard Cite

Although the vasculogenic potential of circulating and cord blood (CB)‐derived endothelial colony‐forming cells (ECFC) has been demonstrated in vitro and in vivo, little is known about the inherent biologic ability of these cells to home to different organs and contribute to tissue‐specific cell populations. Here we used a fetal sheep model of in utero transplantation to investigate and compare the intrinsic ability of human CB‐derived ECFC to migrate to the liver and to the intestine, and to define ECFC's intrinsic ability to integrate and contribute to the cytoarchitecture of these same organs. ECFCs were transplanted by an intraperitoneal or intrahepatic route (IH) into fetal sheep at concentrations ranging from 1.1‐2.6 × 106 cells/fetus. Recipients were evaluated at 85 days posttransplant for donor (human) cells using flow cytometry and confocal microscopy. We found that, regardless of the route of injection, and despite the IH delivery of ECFC, the overall liver engraftment was low, but a significant percentage of cells were located in the perivascular regions and retained the expression of hallmark endothelial makers. By contrast, ECFC migrated preferentially to the intestinal crypt region and contributed significantly to the myofibroblast population. Furthermore, ECFC expressing CD133 and CD117 lodged in areas where endogenous cells expressed those same phenotypes. Conclusion: ECFC inherently constitute a potential source of cells for the treatment of intestinal diseases, but strategies to increase the numbers of ECFC persisting within the hepatic parenchyma are needed in order to enhance ECFC therapeutic potential for this organ. (HEPATOLOGY 2012;56:1086–1096)

show abstract

Reduced Endothelial Progenitor Cell Number and Function in Inflammatory Bowel Disease: A Possible Link to the Pathogenesis

Abstract: We hypothesize that in IBD patients, apoptosis contributes to the reduction of circulating EPC number and to their ability to proliferate in vitro. As this condition represents a risk factor for cardiovascular disease, endothelial function should be evaluated in these patients.

Cited by 32 publications

References 67 publications

The Evolution of Vascular Tissue Engineering and Current State of the Art

The Evolution of Vascular Tissue Engineering and Current State of the Art

Circulating Endothelial Progenitor Cells in Crohn’s Disease: An EPiC in the Making?

Distinct contribution of human cord blood-derived endothelial colony forming cells to liver and gut in a fetal sheep model

Contact Info

Product

Resources

About